EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker‐Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers Initiative

Ethan G. Brown, Lana M. Chahine, Roseanne D. Dobkin, Tanya Simuni, Tatiana Foroud, Laura E.A. Heathers, Thomas F. Tropea, Craig E. Stanley, Bridget A. McMahon, Norbert Brüggemann, Christine Klein, Ronald B. Postuma, Noah S. Johnson, Caroline Gochanour, Chelsea Caspell‐Garcia, Ryan Kurth, Michael C. Brumm, Christopher S. Coffey, Kenneth Marek, Caroline M. Tanner

Annals of Neurology · 2026-10 · 100 (S38)

DOI: 10.1002/ana.78246 ↗
AbstractBibliografische Angaben

Abstract

To better understand the earliest stages of alpha‐synucleinopathy, the Parkinson's Progression Markers Initiative (PPMI) has enrolled participants prior to the diagnosis of Parkinson's disease (PD) or dementia with Lewy Bodies (DLB). In this review, we describe lessons learned from prior enrollment and current strategies for PPMI eligibility. Severe hyposmia remains the strongest clinical predictor of aggregated synuclein as measured by a positive cerebrospinal fluid alpha‐synuclein seed amplification assay (CSF aSyn SAA). CSF aSyn SAA is positive before dopamine transporter binding decreases, as measured by dopamine imaging. PPMI's adaptive eligibility criteria have enabled efficient identification of people in the early stage of neuronal synuclein disease defined by biomarkers alone and can inform future therapeutic studies. ANN NEUROL 2026;100:S26–S35

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →